<DOC>
	<DOCNO>NCT02406443</DOCNO>
	<brief_summary>Background : Dedicated renal hemodynamic renal function study lack DPP-4 inhibitor patient Type 2 diabetes ; accordingly little known regard mechanism mediate renal effect DPP-4 inhibitor human . Objectives : To evaluate effect DPP-4 inhibition acutely ( single dose ) follow short-term therapy ( 28 day ) renal sodium handle renal hemodynamics function patient type 2 diabetes systolic hypertension . Design : double-blind , randomize , placebo-controlled trial , Phase IV . Patient population : 32 patient Type 2 diabetes , HbA1c ( 6.5 % -9 % ) , systolic blood pressure range 120-160 mmHg . Intervention : subject randomize ( 1:1 ) either sitagliptin ( 100 mg daily ) placebo ( 1 tablet daily ) 28 day . Endpoints : Fractional excretion sodium , renal function , renal hemodynamics .</brief_summary>
	<brief_title>The INDORSE Study : Inhibition Dipeptidyl Peptidase IV : Outcomes Renal Sodium Excretion</brief_title>
	<detailed_description>Background : DPP-4 inhibition improve glycemic control , modestly reduce blood pressure may also reduce albuminuria patient Type 2 diabetes ; effect occur without significantly modify heart rate body weight . While preclinical study demonstrate DPP-4 inhibition acutely increase urinary sodium excretion addition favorable renal effect ( anti-inflammatory , anti-proteinuric ) , study examine renal effect DPP-4 inhibition either acutely follow short-term therapy human type 2 diabetes . Considering world-wide prevalence Type 2 diabetes increase use DPP-4 inhibitor amongst patient , important ascertain potential non-glycemic effect DPP-4 inhibitor include within kidney . Study Objectives : To determine effect ( ) DPP-4 inhibition tubular sodium handling , renal hemodynamics , renal function . Study Design : double-blind , randomize , placebo-controlled trial , Phase IV . Study Patients : 32 patient Type 2 Diabetes Systolic Hypertension ( SBP 120-160 mmHg ) . Endpoints : Fractional excretion sodium , renal function ( measure GFR ) , renal hemodynamics ( effective renal plasma flow , filtration fraction , renal blood flow , renal vascular resistance ) , systemic hemodynamics ( non-invasive cardiac monitoring ) , plasma neurohormone , urinary vasoactive mediator , marker free radical stress .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
	<criteria>Individuals 1870 year age , Type 2 Diabetes , HbA1c ( 6.5 % 9 % ) , systolic blood pressure ( 120160 mmHg ) . Individuals : 1 . Type 1 Diabetes , 2. eGFR &lt; 50mL/min/1.73m , 3. pregnancy breast feeding , 4. significant cardiac , pulmonary liver disease , 5. prior history pancreatitis , medullary thyroid cancer , multiple endocrine neoplasia syndrome , 6 . SBP &gt; 161 mmHg , 7 ) DBP &gt; 100 mmHg , 7. alcohol substance abuse , 8. state secondary hypertension .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Type 2 Diabetes , DPP-4 inhibitor , renal sodium excretion</keyword>
</DOC>